Trailing AstraZeneca in lupus, Bristol Myers looks to push TYK2 drug into PhIII trials
In the past year, AstraZeneca has won US and EU approvals for its lupus antibody Saphnelo, which became the first new lupus drug to get …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
